Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NICE recommends Novartis’ Lucentis for NHS use
Ranibizumab is used to treat people with visual impairment due to macular oedema secondary to Retinal Vein Occlusion (RVO). The positive NICE Final Appraisal Determination (FAD) has recommended
Ranibizumab is used to treat people with visual impairment due to macular oedema secondary to Retinal Vein Occlusion (RVO). The positive NICE Final Appraisal Determination (FAD) has recommended
New facility for Bio-Manguinhos will use iBio’s plant-based protein expression technology, iBioLaunch, and GE Healthcare’s expertise in process design and start-to-finish biopharmaceutical and vaccine manufacturing technologies. GE Healthcare
Myrbetriq is indicated to treat OAB with symptoms of urge urinary incontinence, urgency and urinary frequency. The University of Western Ontario urology adjunct professor, St. Mary’s General Hospital
As part of the agreement, Inventiva and NovAliX offer pharmaceutical and biotech companies a set of fully integrated nuclear receptor drug discovery capabilities. The collaboration will use both
Ubiquinol, which is the active antioxidant form of coenzyme Q10 (CoQ10), supports cardiovascular health and transforms food into energy. Nordic Naturals chief medical officer Keri Marshall said that
The trial will be conducted at Massachusetts General Hospital (MGH), the University of Massachusetts (UMass) Hospital and the Mayo Clinic. Dana-Farber’s Connell and O’Reilly Cell Manipulation Core plant
Tykerb in combination with capecitabine is indicated to treat advanced or metastatic breast cancer patients whose tumors overexpress HER2 and who were previously treated with anthracycline, a taxane
The new North America Headquarters accomodates company’s generics, biologics, PSAI and proprietary product businesses in addition to the corporate support functions within North America. Dr. Reddy’s chairman and
The technology leverages immunotherapeutic IgE to develop treatment for cancer patients expressing the tumor-associated antigen PSA that is coupled with prostate cancer. The anti-PSA monoclonal IgE demonstrated ability
At present, Priligy is being marketed for premature ejaculation in 16 countries in Europe, Asia and Latin America and approved for the same indication in 56 countries across